Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $2.7 million.

  • Vivos Therapeutics' Accumulated Expenses rose 3057.45% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 3057.45%. This contributed to the annual value of $2.2 million for FY2024, which is 428.45% down from last year.
  • Vivos Therapeutics' Accumulated Expenses amounted to $2.7 million in Q3 2025, which was up 3057.45% from $2.3 million recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Accumulated Expenses high stood at $3.2 million for Q1 2022, and its period low was $1.8 million during Q1 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $2.3 million (2025), whereas its average is $2.3 million.
  • Per our database at Business Quant, Vivos Therapeutics' Accumulated Expenses soared by 6424.87% in 2021 and then crashed by 3883.98% in 2023.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Accumulated Expenses stood at $2.9 million in 2021, then crashed by 32.98% to $1.9 million in 2022, then grew by 22.07% to $2.3 million in 2023, then decreased by 4.28% to $2.2 million in 2024, then grew by 20.05% to $2.7 million in 2025.
  • Its Accumulated Expenses was $2.7 million in Q3 2025, compared to $2.3 million in Q2 2025 and $1.8 million in Q1 2025.